Background: Disparities in cancer care have not been well documented for individuals with disability.
Objective: To investigate potential disparities in the diagnosis, treatment, and survival of prostate cancer (PC) patients according to disability status.
Methods: A retrospective cohort study using disability registration data linked to Korean National Health Insurance and national cancer registry data. Totals of 7924 prostate cancer cases among patients with disabilities (diagnosed between 2005 and 2013) and 34,188 PC patients without disability were included.
Results: While overall PC stage distribution at diagnosis was similar, unknown stage was more common in patients with severe disabilities compared to those without disabilities (18.1% vs. 16.2%, respectively). People with disabilities were less likely to undergo surgery (33.1% vs. 38.6%, respectively; adjusted odds ratio [aOR] 0.79, 95% confidence interval [CI] 0.74-0.84), and more likely to receive androgen deprivation therapy (ADT) (57.9% vs. 55%, respectively; aOR 1.10, 95% CI 1.04-1.16) compared to those without disabilities. This was more evident for people with severe brain/mental impairment (aORs 0.29 for surgery; 1.52 for ADT). Patients with disabilities had higher overall mortality (adjusted hazard ratio [aHR] 1.20; 95% CI, 1.15-1.25), but only slightly higher PC-specific mortality after adjustment for patient factors and treatment (aHR 1.11, 95% CI 1.04-1.18) than people without disability.
Conclusions: PC patients with disabilities underwent less staging work-up and were more likely to receive ADT than surgical treatment. Overall mortality of PC patients with disabilities was greater than those of PC patients without disability, but PC-specific mortality was only slightly worse.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dhjo.2021.101125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Musculoskeletal ultrasonography versus conventional radiography: Correlation with DAS28 and MDHAQ scores in early rheumatoid arthritis.
J Int Med Res
December 2024
Department of Rheumatology and Rehabilitation, RinggoldID:63527 Cairo University, Cairo, Egypt.
Objectives: To compare the value of musculoskeletal ultrasound (MSUS) with conventional radiography in the detection of patients with early rheumatoid arthritis (RA) and to correlate the sonographic findings with disease activity, and functional disability scores.
Methods: Patients >18 years of age with RA ≤2 years who satisfied the 2010 EULAR/ACR classification criteria for rheumatoid arthritis and disease activity score 28 (DAS28) >2.6, were enrolled.
[Modern aspects of chronic cerebral ischemia pathogenetic therapy].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
S.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Chronic cerebral ischemia (CCI) is one of the most common forms of cerebrovascular disease, which affects a significant number of patients, often leading to disability, cognitive impairment and dementia. The analysis of modern data on the pathogenesis and risk factors for the development of CCI, as well as on the mechanisms of action of Mexidol on various links in the pathogenesis of CCI. A systematic search was conducted in the PubMed, MEDLINE and Google Scholar databases, on Russian and English-language sites with open access publications on the problem of CCI and on the drug Mexidol in the period from 2014 to 2024.
View Article and Find Full Text PDF[Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).
Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.
[Quality of life of patients with multiple sclerosis in the Smolensk region].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
From spastic paraplegia to infantile neurodegenerative disorder: Expanding the phenotypic spectrum associated with biallelic SPAST variants.
Eur J Neurol
January 2025
Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.
Purpose: Heterozygous pathogenic variants in SPAST are known to cause Hereditary Spastic Paraplegia 4 (SPG4), the most common form of HSP, characterized by progressive bilateral lower limbs spasticity with frequent sphincter disorders. However, there are very few descriptions in the literature of patients carrying biallelic variants in SPAST.
Methods: Targeted Sanger sequencing, panel sequencing and exome sequencing were used to identify the genetic causes in 9 patients from 6 unrelated families with symptoms of HSP or infantile neurodegenerative disorder.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!